MedCity News March 26, 2023
In recent years, manufacturers have restricted access to 340B pricing for drugs dispensed through contract pharmacies. The federal government has advised manufacturers that such restrictions are unlawful, and manufactures have challenged government enforcement actions in federal court.
A recent federal appeals court decision is creating uncertainty for pharmacies and healthcare providers that participate in the federal 340B drug pricing program, which requires drug manufacturers to offer discounted prices for drugs sold to providers serving a high volume of low-income or rural patients.
340B covered entities, including hospitals, federally qualified health centers (FQHCs) and other types of safety net clinics, commonly dispense drugs purchased at 340B prices through pharmacies under contract with a 340B entity. In recent years, however, manufacturers have...
Today's Sponsors
Today's Sponsor